Dipeptidyl peptidase-4 inhibitor and sodium-glucose cotransporter 2 inhibitor additively ameliorate hepatic steatosis through different mechanisms of action in high-fat diet-fed mice.
Yuichiro IwamotoTomohiko KimuraKazunori DanHideyuki IwamotoJunpei SanadaYoshiro FushimiYukino KatakuraMasashi ShimodaYuka NogamiYoshiko ShirakiyaShuhei NakanishiTomoatsu MuneKohei KakuHideaki KanetoPublished in: Diabetes, obesity & metabolism (2024)
The combination therapy with the DPP-4 inhibitor anagliptin and the SGLT2 inhibitor luseogliflozin inhibits fat deposition in the liver via anti-inflammatory effects during the early phase of diet-induced liver steatosis.